Loading clinical trials...

Acute Hip Fracture Study in Patients 65 Years or Greater | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Acute Hip Fracture Study in Patients 65 Years or Greater

A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects With Acute Hip Fracture

NCT02578095•Viking Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment. Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be eligible for participation 3-7 weeks post-injury.

Eligibility

Age

65 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Males or females ≥65 years old who are recovering from a hip fracture (occurring 3-7 weeks prior) with no residual surgical issues will be eligible for participation.

Exclusion Criteria

•Pathological fracture (e.g. fracture due to Paget's disease of bone, malignancy, etc.). Fracture due to postmenopausal osteoporosis is not considered pathological for this trial.

Locations (21)

Duurga Clinical Service

Yorba Linda, California, United States

Orthopedic Research Institute

Boynton Beach, Florida, United States

Infinite Clinical Research

Doral, Florida, United States

Shrock Orthopedic Research, LLC

Fort Lauderdale, Florida, United States

Center for Advanced Research & Education

Gainesville, Georgia, United States

Orthopaedic Association of Michigan

Grand Rapids, Michigan, United States

University of Wisconsin Osteoporosis Clinical Research Program

Madison, Wisconsin, United States

Szent János Kórház és Észak budai Egyesített Kórházak Traumatológiai és Kézsebészeti Osztály

Budapest, Hungary

MH Egészségügyi Központ Baleseti Sebészeti Osztály

Budapest, Hungary

Szent Margit Kórház, Mozgásszervi Rehabilitációs Osztály

Budapest, Hungary

Key Dates

Start Date

October 30, 2015

Primary Completion Date

November 15, 2017

Completion Date

December 17, 2017

Last Updated

December 29, 2025

Enrollment

108

ACTUAL participants

Conditions

Hip Fractures

Interventions

VK5211

DRUG

Placebo

DRUG

Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)

NCT06565910

Femoral Neck FracturesFemur Head Necrosis+1 more

View study

RECRUITINGNA

One Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures

NCT07432737

Hip Fractures

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Acute Hip Fracture Study in Patients 65 Years or Greater

Inclusion Criteria

Exclusion Criteria

Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)

One Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures

Evaluation of Fracture Migration After Internal Fixation of Femoral Neck Fractures in Younger Adults: A Clinical RCT Using RSA

Comparison of Cryoablation of Pericapsular Nerve Group (PENG) to Fascia Iliaca Catheter in Patients With a Hip Fracture

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

PENG vs Femoral Block for Hip Fracture Analgesia